{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'No dose-related trend was observed in any of the laboratory, physical exam or EKG results. No', 'consistent dose relationship or clear difference between the 50 mg and 80 mg dose groups was', 'observed with respect to incidence of AEs, SAEs or laboratory tests.', \"A more detailed summary of clinical safety data is presented in the Investigator's Brochure.\", '1.2.2.3.', 'Summary of Pharmacokinetic and Pharmacodynamic Effects in', 'ALN-AT3SC-001 and ALN-AT3SC-002', 'Consistent with the intended pharmacological effects, regardless of inhibitor status, fitusiran', 'dose-related reductions in AT activity level have been observed in the clinical studies, and have', 'been associated with increased thrombin generation. In Part C of the Phase 1 study, the mean', 'maximum AT activity level reductions following 3 monthly doses of 0.225, 0.45, 0.9 or 1.8', 'mg/kg fitusiran were 70% (N=3), 77% (N=3), 77% (N=3), and 89% (N=3), respectively. A', 'fixed dose, 80 mg fitusiran, was also explored in Part C, resulting in a mean maximum AT', 'activity level reduction of 87% (N=6). In Part D of the study, patients with inhibitors were dosed', 'with 50 or 80 mg fitusiran and experienced mean maximum AT activity level reduction of 82%', '(N=6) and 87% (N=10), respectively. AT reduction was maintained in ALN-AT3SC-002, with', 'mean maximal AT reduction of 83.6% for 50 mg (N=13) and 85.9% for 80 mg (N=21) as of', '08 Aug 2017.', 'Consistent with the therapeutic hypothesis, increased AT lowering in patients with hemophilia', 'resulted in increased thrombin generation when AT lowering was in the highest quartile (>75%)', 'compared to when AT lowering was in the lowest quartile (<25%). Further, the peak thrombin', 'generation values achieved with AT lowering of >75% were comparable to those in the lower', 'end of the normal range observed in healthy individuals. None of the thrombin generation', 'measurements following >75% AT reduction in hemophilia patients exceeded those seen in', 'healthy males.', '1.3.', 'Study Design Rationale', 'The ATLAS-INH trial (ALN-AT3SC-003 [Sanofi Genzyme EFC14768]) is a multicenter,', 'multinational, randomized, open-label Phase 3 study designed to demonstrate the efficacy and', 'safety of fitusiran in patients with hemophilia A or B with inhibitory antibodies to FVIII or FIX', 'who are currently treated with on-demand BPAs.', 'The primary objective is to assess the efficacy of fitusiran on prevention or reduction of bleeding', 'episodes. Secondary objectives are to assess the efficacy of fitusiran on: the number and type of', 'bleeding episodes; HRQOL; and to determine the safety and tolerability of fitusiran.', 'Blinding is not considered feasible for this study since differences in treatment for each study', 'arm cannot be blinded. The open-label, randomized study design is justified because safety', 'monitoring of theoretical risks such as transaminitis or thrombosis can be objectively verified by', 'laboratory monitoring or objective visualization, eg, ultrasound or CT. Therefore, the safety', 'monitoring of the studied population does not require blinding.', 'The primary endpoint of the study is ABR in the fitusiran efficacy period (Day 29 to EOS).', 'ABR is a well-established endpoint that has been used as the primary endpoint in global', 'approvals of factor replacement and BPA products. Secondary endpoints characterize ABR in', 'the treatment period, annualized spontaneous and joint bleeding rates, change in Hemophilia', 'Property of the Sanofi Group - strictly confidential', '31']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Quality of Life Questionnaire for Adults (Haem-A-QOL) physical health score and total score in', 'patients >17 years of age, ABR in the onset period, and the overall safety profile.', 'Characterization of bleeding episodes is clinically relevant to assess overall bleeding episode', 'protection. Joint bleeding episodes result in pain and hemarthrosis, leading to progressive joint', 'destruction, and hence are important to assess. The Haem A-QOL is a hemophilia-specific', 'HRQOL survey instrument that has been validated in other hemophilia clinical trials and is', 'considered the most appropriate HRQOL tool for this study.', 'The study population will be comprised of males >12 years of age; it is appropriate to study', 'fitusiran in adolescents (patients >12 to <18 years of age) because the pathophysiology of disease', 'progression and bleeding episode management is the same as adults and self-management of', 'hemophilia typically begins at 12 years of age.[6] A similar study in hemophilia patients without', 'inhibitors (ALN-AT3SC-004 [EFC14769]) is being conducted concurrently to this study.', 'To protect against bias, patients will be assigned to fitusiran (fitusiran treatment arm; N=36) or', 'on-demand BPA therapy (on-demand arm; N=18) by stratified randomization.', 'The onset period duration reflects modeling data that estimates it takes approximately 28 days to', 'reach the therapeutic target range in the majority of patients. Efficacy of fitusiran will be', 'assessed over the remaining 8 months of the study (Day 29 to Month 9).', 'In the event of a breakthrough bleeding episode, on-demand use of BPAs will be permitted', 'throughout the entire study duration (see Section 6.3.1).', '1.4.', 'Dose Rationale', 'Dose selection was guided by the principle of identifying an optimal dose that is both', 'well-tolerated and efficacious. The fitusiran dose proposed for Phase 3 development was', 'identified based on observed data from ongoing clinical studies, as well as extensive clinical', 'simulations and modeling. The key PD and clinical parameters used to support the dose', 'selection include decreases in AT activity, the most proximate and direct PD effect of fitusiran,', 'as well as increases in thrombin generation and decreases in ABR.', 'Observed data from Phase 1 and Phase 1/2 studies in patients with hemophilia A and B, with or', 'without inhibitors, and PK/PD modeled data, support selection of a fixed dose of 80 mg for this', 'study, as subcutaneously administered once-monthly.', 'In observed data from Phase 1 and Phase 1/2 studies, monthly equivalent doses or monthly doses', 'ranging from 0.045 mg/kg to 1.8 mg/kg and fixed doses of 50 mg and 80 mg have been', 'evaluated. A clear dose response trend of increased AT lowering is evident, with approximately', '10% to 20% residual AT activity at a dose of 1.8 mg/kg and at fixed doses of 50 mg and 80 mg', 'subcutaneously administered once monthly. These data suggest that the maximum AT lowering', 'achieved as a function of the dose administered reaches an asymptote at ~90% AT lowering and', 'that it is unlikely higher doses will achieve meaningfully greater AT lowering. In addition, both', 'the 50 mg and 80 mg fixed doses produced substantial increases in peak thrombin generation,', 'which approach the lower end of the normal range, but do not exceed the normal range.', 'Dose-response modeling analyses are supportive of the observed data. A repeated time to event', 'model was used to evaluate the relationship between AT lowering and the anticipated ABR.', 'According to the model, the 80 mg, fixed, once-monthly dose is anticipated to result in near', 'Property of the Sanofi Group - strictly confidential', '32']\n\n###\n\n", "completion": "END"}